Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma.

J Hepatocell Carcinoma · 2022 · PMC9569161 · PMID 36254201

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Although not statistically significant, increases in IGF-1 or IGF-CTP scores showed a trend toward poorer PFS in both treatment arms ( Supplementary Figure 3A – D ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.